Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.

Autor: Galletta TJ; Cincinnati Children's Hospital Medical Center Cancer and Blood Diseases Institute, Cincinnati, Ohio, USA., Rubinstein JD; Cincinnati Children's Hospital Medical Center Division of Oncology, Cincinnati, Ohio, USA.; University of Cincinnati College of Medicine Department of Pediatrics, Cincinnati, Ohio, USA., Krupski C; University of Cincinnati College of Medicine Department of Pediatrics, Cincinnati, Ohio, USA.; Cincinnati Children's Hospital Medical Center Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, Ohio, USA., Nelson AS; University of Cincinnati College of Medicine Department of Pediatrics, Cincinnati, Ohio, USA.; Cincinnati Children's Hospital Medical Center Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, Ohio, USA., Khoury R; University of Cincinnati College of Medicine Department of Pediatrics, Cincinnati, Ohio, USA.; Cincinnati Children's Hospital Medical Center Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, Ohio, USA., Dandoy CE; University of Cincinnati College of Medicine Department of Pediatrics, Cincinnati, Ohio, USA.; Cincinnati Children's Hospital Medical Center Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, Ohio, USA., Davies SM; University of Cincinnati College of Medicine Department of Pediatrics, Cincinnati, Ohio, USA.; Cincinnati Children's Hospital Medical Center Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, Ohio, USA., Phillips CL; Cincinnati Children's Hospital Medical Center Division of Oncology, Cincinnati, Ohio, USA.; University of Cincinnati College of Medicine Department of Pediatrics, Cincinnati, Ohio, USA.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2023 May; Vol. 70 (5), pp. e30271. Date of Electronic Publication: 2023 Feb 23.
DOI: 10.1002/pbc.30271
Abstrakt: CD19-directed chimeric antigen receptor T lymphocytes (CAR-T) have led to durable remissions in children with refractory and/or multiply relapsed B-lymphoblastic leukemia. For those who relapse or lose B-cell aplasia post CAR-T, the role of CAR-T reinfusion is unclear. We report two cases of durable remission with tisagenlecleucel reinfusion despite failure to achieve or maintain B-cell aplasia, and compare these cases to six additional children who received multiple tisagenlecleucel infusions at our institution. Our experience suggests that reinfusion is safe and may be a definitive therapy for a small subset of patients. Reinfusion can also reintroduce remission and/or B-cell aplasia, allowing for subsequent therapies.
(© 2023 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: